A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT04660539 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG: satralizumab
DRUG: azathioprine (AZA)
DRUG: mycophenolate mofetil (MMF)
DRUG: oral corticosteroids

Sponsor

Hoffmann-La Roche